Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee

Tempest Therapeutics, Inc.

Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.
Retained MTS Health Partners to evaluate M&A, partnerships, licensing or other transactions.
Amezalpat (TPST-1120) Phase 3-ready with FDA and EMA interactions; Orphan Drug and Fast Track designations in HCC.
TPST-1495 received FDA 'Study May Proceed' for Phase 2 in FAP; data expected 2026.
Company cites unavailable capital markets as reason to seek a strategic partner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.